Clls stock price
WebView the latest Cellectis S.A. ADR (CLLS) stock price, news, historical charts, analyst ratings and financial information from WSJ. WebCLLS Valuation Summary. CLLS's price/earnings ratio is -1; this is 104.27% lower than that of the median Healthcare stock. Over the past 96 months, CLLS's price/earnings ratio …
Clls stock price
Did you know?
WebApr 11, 2024 · Stock Screener Top Online Growth Stocks Trending Stocks Penny Stock Screener. ... North Carolina. Cellectis is listed on the Nasdaq Global Market (ticker: CLLS) and on Euronext Growth (ticker: ALCLS). ... The Fly Cellectis price target lowered to $16 from $24 at Citi. 6d ago. CLLS. WebApr 4, 2024 · The EIB Warrants will have an exercise price per share equal to €1.92, corresponding to 99% of the weighted average price per share of Cellectis over the last 3 trading days prior to their issuance. ... Cellectis (NASDAQ:CLLS) Historical Stock Chart From Apr 2024 to Apr 2024 Latest CLLS Messages {{bbMessage.M_Alias}} …
WebNASDAQ:CLLS: NASDAQ: Common Stock Price Change % Change Share Price Bid Price Offer Price : 0.00: 0.0%: 1.97: 1.81: 1.99: High Price Low Price Open Price Shares Traded Last Trade; 1.99: 1.89: 1.99: 44,698: 22:16:11: Cellectis (CLLS) News Headlines. Real-Time news about Cellectis SA (NASDAQ): 0 recent articles ... WebCLLS Stock Price - Cellectis SA operates as a clinical stage biotechnological company, which engages in gene-editing platform to develop cell and gene therapies. ... It’s …
WebMar 17, 2024 · Check if CLLS Stock has a Buy or Sell Evaluation. CLLS Stock Price (NASDAQ), Forecast, Predictions, Stock Analysis and Cellectis S.A. News. ... The Cellectis S.A. stock price gained 1.08% on the last trading day … WebAccording to our current CLLS stock forecast, the value of Cellectis S.A. shares will rise by 5.17% and reach $ 2.05 per share by April 7, 2024. According to our technical indicators, the current sentiment is Bearish while the Fear & Greed Index is showing 39 (Fear).CLLS stock recorded 6/30 (20%) green days with 13.38% price volatility over the last 30 days.
WebApr 11, 2024 · The average 1 year price objective among brokerages that have issued a report on the stock in the last year is $8.57. A number of research firms recently commented on CLLS.
WebWall Street Stock Market & Finance report, prediction for the future: You'll find the Clover Health Investments Corp - Class A share forecasts, stock quote and buy / sell signals below. According to present data Clover Health Investments Corp - Class A's CLOV shares and potentially its market environment have been in bearish cycle last 12 ... flushing veterinarianWebFind the latest Calyxt, Inc. (CLXT) stock quote, history, news and other vital information to help you with your stock trading and investing. flushing veterinary clinicWebApr 11, 2024 · The average 1 year target price among brokerages that have covered the stock in the last year is $8.57. A number of equities research analysts have issued reports on CLLS shares. flushing view newspaperWebApr 6, 2024 · According to 10 analysts, the average rating for CLLS stock is "Buy." The 12-month stock price forecast is $23.95, which is an increase of 1,163.85% from the latest … green fork baptist church perkins gaWebApr 12, 2024 · 7 brokers have issued twelve-month price targets for Atara Biotherapeutics' stock. Their ATRA share price forecasts range from $3.00 to $50.00. On average, they expect the company's share price to reach $19.25 in the next year. This suggests a possible upside of 594.9% from the stock's current price. View analysts price targets for ATRA … green fork baptist church millen gaWebIt's typically categorized as a valuation metric and is most often quoted as Cash Flow per Share and as a Price to Cash flow ratio. In this case, it's the cash flow growth that's being looked at ... green fork animal hospitalWebApr 11, 2024 · The BALLI-01 study (evaluating UCART22) is actively enrolling patients with relapsed or refractory B-cell ALL after FCA lymphodepletion. NEW YORK, April 11, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing … green fork covington la